Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-10-26 Regulatory Filings
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a specific operational update: receiving regulatory approvals to resume a clinical study (EFICAS study) in France for their medical device (Aeson®). This type of announcement, detailing operational milestones, regulatory interactions, and business updates outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or investor relations communications. Since it is a formal announcement of a significant event, but not a core financial report, a dividend notice, or a management change, it best fits the general category for regulatory/corporate announcements. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard corporate news releases that aren't covered by more specific codes like ER, CAP, or MANG. It is not a Call Transcript (CT), Earnings Release (ER), or a comprehensive financial report (10-K/IR).
2022-10-26 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a significant operational update: CARMAT receiving regulatory approvals to resume commercial implants of its Aeson® heart. This type of announcement, detailing key operational milestones, regulatory achievements, or financial highlights outside of a formal quarterly/annual filing, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal press release announcing a major business event (regulatory clearance) and includes quotes from the CEO, it fits best under the 'Earnings Release' category, which often encompasses major operational news releases, or 'Regulatory Filings' as a general announcement. Given the content is a major business update rather than just a notice of a report being available, ER is a strong candidate. However, since it is not explicitly reporting financial results (like revenue or EPS) but rather regulatory/operational progress, and it is a general announcement, RNS (Regulatory Filings - the fallback for miscellaneous regulatory announcements) is also plausible. Comparing the definitions, ER is for initial announcements of periodical financial results (key highlights only). This is an operational/regulatory highlight. Since it is a formal press release announcing a major event, and it doesn't fit perfectly into the specific operational/financial categories (like 10-K, IR, CT), RNS serves as the appropriate general regulatory announcement category for significant, non-standard updates. Given the context of a major operational/regulatory milestone announcement via a press release, RNS is the most appropriate general classification.
2022-10-25 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that CARMAT has obtained the necessary regulatory authorizations (from DEKRA) to resume commercial implantations of its Aeson® artificial heart. This type of announcement, which communicates a significant operational or regulatory event via a press release format, typically falls under general regulatory announcements or news releases. Since it is not a full financial report (10-K, IR), a specific financial event (CAP, DIV), or a management change (MANG), the most appropriate general category for a significant, non-financial regulatory/operational update disseminated broadly is Regulatory Filings (RNS), as it serves as a general regulatory announcement. It is not an Earnings Release (ER) as it does not focus on financial results, nor is it an Investor Presentation (IP) or Fund Factsheet (FS). It is a direct announcement of a regulatory milestone enabling commercial activity.
2022-10-25 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that CARMAT has three scientific publications regarding its Aeson® artificial heart in peer-reviewed journals. The text summarizes the findings of these publications and includes a quote from the CEO. Crucially, the document is an announcement *about* reports/data, not the full financial report itself (like 10-K or IR). Since it is a press release announcing scientific/data updates, it does not fit perfectly into the core financial filing types (10-K, IR, ER). It is a general corporate announcement. Given the options, this type of announcement, which is not a standard regulatory filing like a 10-K or a specific event like an AGM or Earnings Release, is best categorized as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a deck, but as a press release announcing external publications, RNS serves as the most appropriate general regulatory/corporate announcement fallback, although it is highly specific scientific news. However, since it is a press release announcing external scientific data, and not a formal financial report, RNS (Regulatory Filings / General Regulatory Announcements) is the best fit among the provided codes for a non-standard, non-financial-results announcement.
2022-10-18 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that CARMAT is releasing information about three scientific publications concerning their Aeson® device. It details the content of these publications (clinical results, hemocompatibility, absence of inflammation) and includes commentary from the CEO. This format—a brief announcement summarizing external information (scientific papers) released to the public and investors—is characteristic of a general press release or an announcement regarding corporate activity. Since it is not a full financial report (10-K, IR), a specific financial event (ER, CAP), or a formal regulatory filing like a proxy statement, the most appropriate classification is a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format announcing external scientific validation, RNS serves as the best fit among the provided options for a non-standard, informational corporate announcement. Applying the 'MENU VS MEAL' rule: This is an announcement *about* publications, not the publications themselves, and it is short enough to be considered an announcement rather than a comprehensive report. However, since the core content is the announcement of scientific validation, and RNS is the general regulatory/miscellaneous announcement category, RNS is selected over RPA (which is usually for announcing the *timing* of a report release).
2022-10-18 English
Informations privilégiées / Communiqué sur comptes, résultats
Interim / Quarterly Report Classification · 1% confidence The document is a press release from CARMAT titled 'CARMAT publie ses résultats semestriels 2022' (CARMAT publishes its 2022 half-year results). It contains key financial highlights, a simplified income statement, cash flow data, and management commentary regarding the company's strategic objectives and operational status. While it references a full financial report, the document itself provides the substantive financial data and analysis for the interim period, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-15 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.